VRTX - 44% Ramp from August - How much more of a Premium for a Pharma bid? NEW YORK (TheStreet) -- My biotech stock predictions for 2015. (BY David Sobek) 1. Drug pricing fears finally catch up to the biotech sector and the multi-year bull market ends. However, the closely watched biotech stock indices churn up [...]
By Emily Wasserman A new voice is joining the patent-fighting chorus. U.S. hedge fund manager Kyle Bass, best known for predicting the subprime mortgage crisis in 2008, said he plans to challenge "questionable" drug patents held by industry heavyweights. Bass plans to challenge 15 drug companies' patents via an Inter Partes Review (IPR) process created [...]
Upside traction in the Pharma's indicate plenty of capital for R&D...
by Anette Breindl, PhD Twenty-four years after the National Institutes of Health (NIH) established the Office of Research on Women’s Health, and 21 years after the NIH Revitalization Act of 1993 first required that women be included in clinical trials, certainly the letter of the law has been achieved. Women are now the majority of participants [...]
CytomX Therapeutics Inc. grabbed $20 million led by Pfizer Inc.'s venture capital arm to help partner its sneaky cancer fighters with new types of drugs and build out its own portfolio. The investment, disclosed Tuesday, comes after CytomX on Monday announced a trio of key hires, including former Five Prime Therapeutics chief scientific officer Dr. [...]
What does Crude Oil have to do with Pharma? As oil plunges, so does the capital needed for R&D.
By Tracy Staton The shake-up at the top of Salix Pharmaceuticals continues. On Monday afternoon, CEO Carolyn Logan became the second C-suite executive to step down in the wake of an inventory snafu disclosed late last year. Logan will retire as of Jan. 30, the company said. CFO Adam Derbyshire made his exit in [...]
GSK - NYSE - Nasty Chart, looks like a test of the 2012 low is coming. GlaxoSmithKline ($GSK) is making big cost cuts to boost its finances next year as sales of its $8.25 billion asthma med Advair are deflated by competition, generic and otherwise. With the U.S. being the biggest market for the [...]
Since its lows in mid-October, biotech stocks have sparkled, particularly the Big four – Amgen (AMGN), Biogen Idec (BIIB), Celgene (CELG), and Gilead (GILD) – which have demonstrated sustainable growth pathways. With the market’s renewed volatility in recent days, they have pulled back some, which only made them much more reasonably priced. But the more [...]
We have bad news and good news about patent expirations next year. The bad? When you tot up the billions of sales at risk of patent expiration in 2015, the result is $44 billion, the biggest number since the debacle of 2012. That year, $53 billion worth of drugs fell off patent--and many drugmakers are [...]
